Sacubitril/Valsartan vs Standard Heart Drugs: Who Benefits Most from the Natriuretic Peptide Approach

In a meta-analysis of 14 randomized trials (25,167 patients), sacubitril/valsartan reduced heart failure rehospitalization by 15% compared to ACE inhibitors or ARBs regardless of ejection fraction (RR: 0.85; P=0.00001). All-cause mortality was reduced by 12% but only in patients with ejection fraction ≤40% (RR: 0.88; P=0.0006) — no mortality benefit was seen in patients with higher ejection fractions. Notably, cardiovascular mortality was not significantly reduced in any ejection fraction group.

Systematic review and meta-analysis of randomized clinical trials comparing sacubitril/valsartan to ACE inhibitors or ARBs. Databases searched: PubMed, EMBASE, Scopus, Cochrane Central Register (inception to November 2023). Random effects model used. Risk ratios with 95% CI reported. Heterogeneity assessed with I² test. Publication bias assessed via funnel plots and Egger test. Registered in PROSPERO (CRD42024497661).

Sacubitril/valsartan works by blocking neprilysin — the enzyme that breaks down natriuretic peptides — allowing these protective peptides to remain active longer. This meta-analysis clarifies which heart failure patients benefit most: those with reduced ejection fraction get both fewer hospitalizations and lower mortality, while those with preserved ejection fraction only get fewer hospitalizations. This distinction helps clinicians target the drug to the right patients.

Sacubitril/valsartan is the most prominent drug that works by enhancing natriuretic peptide signaling — it blocks the enzyme (neprilysin) that degrades BNP and ANP, letting these protective peptides work longer. This meta-analysis refines our understanding of where this peptide-boosting strategy works best: the clearest benefits are in reduced-ejection-fraction heart failure, where natriuretic peptide enhancement translates to both fewer hospitalizations and longer survival.

Results for cardiovascular mortality did not reach statistical significance, which may reflect insufficient power for this specific endpoint. The EF>40% subgroup showed no mortality benefit, but fewer trials may have been available in this population. Individual trial designs and populations varied across the 14 included studies.